Eosinophilia as a Predictive Biomarker for Melanoma Treatment, A Single Center Review

Daniel Y. Reuben
Additional contact information
Daniel Y. Reuben: Department of Medicine, Medical University of South Carolina, USA

Biomedical Journal of Scientific & Technical Research, 2023, vol. 53, issue 1, 44260-44269

Abstract: Responses to immune checkpoint inhibitor (ICI) therapy is variable with regards to response type and duration with patients with melanoma. To date an arbitrary treatment duration is applied in absence of clear biomarkers which could otherwise guide therapy. Eosinophilia has recently been investigated to assess its utility as a biomarker with respect to ICI use in this disease.

Keywords: Journals on Medical Drug and Therapeutics; Journals on Emergency Medicine; Physical Medicine and Rehabilitation; Journals on Infectious Diseases Addiction Science and Clinical Pathology; Open Access Clinical and Medical Journal; Journals on Biomedical Science; List of Open Access Medical Journal; Journals on Biomedical Engineering; Open Access Medical Journal; Biomedical Science Articles; Journal of Scientific and Technical Research (search for similar items in EconPapers)
Date: 2023
References: Add references at CitEc
Citations:

Downloads: (external link)
https://biomedres.us/pdfs/BJSTR.MS.ID.008338.pdf (application/pdf)
https://biomedres.us/fulltexts/BJSTR.MS.ID.008338.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:abf:journl:v:53:y:2023:i:1:p:44260-44269

DOI: 10.26717/BJSTR.2023.53.008338

Access Statistics for this article

Biomedical Journal of Scientific & Technical Research is currently edited by Robert Thomas

More articles in Biomedical Journal of Scientific & Technical Research from Biomedical Research Network+, LLC
Bibliographic data for series maintained by Angela Roy ().